These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18649964)

  • 1. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
    Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.
    Mahy P; De Bast M; Leveque PH; Gillart J; Labar D; Marchand J; Gregoire V
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1263-72. PubMed ID: 15197503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
    Dubois L; Landuyt W; Cloetens L; Bol A; Bormans G; Haustermans K; Labar D; Nuyts J; Grégoire V; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):209-18. PubMed ID: 18690432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
    Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
    J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.
    Mahy P; Geets X; Lonneux M; Levêque P; Christian N; De Bast M; Gillart J; Labar D; Lee J; Grégoire V
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1282-9. PubMed ID: 18317752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
    Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
    J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.
    Riedl CC; Brader P; Zanzonico P; Reid V; Woo Y; Wen B; Ling CC; Hricak H; Fong Y; Humm JL
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):39-46. PubMed ID: 17786438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.
    Christian N; Bol A; De Bast M; Labar D; Lee J; Mahy P; Grégoire V
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1348-54. PubMed ID: 17334763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
    Zanzonico P; O'Donoghue J; Chapman JD; Schneider R; Cai S; Larson S; Wen B; Chen Y; Finn R; Ruan S; Gerweck L; Humm J; Ling C
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):117-28. PubMed ID: 14523586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).
    Maier FC; Kneilling M; Reischl G; Cay F; Bukala D; Schmid A; Judenhofer MS; Röcken M; Machulla HJ; Pichler BJ
    Radiat Oncol; 2011 Nov; 6():165. PubMed ID: 22118419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of [18F]FETNIM: a potential marker for PET.
    Grönroos T; Eskola O; Lehtiö K; Minn H; Marjamäki P; Bergman J; Haaparanta M; Forsback S; Solin O
    J Nucl Med; 2001 Sep; 42(9):1397-404. PubMed ID: 11535732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.
    Christian N; Deheneffe S; Bol A; De Bast M; Labar D; Lee JA; Grégoire V
    Radiother Oncol; 2010 Nov; 97(2):183-8. PubMed ID: 20304513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent.
    Yamamoto F; Aoki M; Furusawa Y; Ando K; Kuwabara Y; Masuda K; Sasaki S; Maeda M
    Biol Pharm Bull; 2002 May; 25(5):616-21. PubMed ID: 12033502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
    Mahy P; De Bast M; Gillart J; Labar D; Grégoire V
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):553-6. PubMed ID: 16523307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia.
    Yamamoto F; Oka H; Antoku S; Ichiya Y; Masuda K; Maeda M
    Biol Pharm Bull; 1999 Jun; 22(6):590-7. PubMed ID: 10408232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
    Wack LJ; Mönnich D; van Elmpt W; Zegers CM; Troost EG; Zips D; Thorwarth D
    Acta Oncol; 2015; 54(9):1370-7. PubMed ID: 26203928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
    Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors.
    Wong KH; Wallen CA; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):135-43. PubMed ID: 2745188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.